Jazz Pharmaceuticals plc Operating Lease Cost
Jazz Pharmaceuticals plc (JAZZ) reported Operating Lease Cost of $23.92 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-24
- Jazz Pharmaceuticals plc operating lease, cost for the quarter ending 2021-12-31 was $5.09M, a 8.41% decline year-over-year.
- Jazz Pharmaceuticals plc operating lease, cost for the quarter ending 2021-09-30 was $6.63M, a 20.56% increase year-over-year.
- Jazz Pharmaceuticals plc operating lease, cost for the quarter ending 2021-06-30 was $6.60M, a 22.07% increase year-over-year.
- Jazz Pharmaceuticals plc operating lease, cost for the quarter ending 2021-03-31 was $5.55M, a 4.84% increase year-over-year.
- Jazz Pharmaceuticals plc operating lease, cost for fiscal 2025 was $23.92M, a 7.71% increase from fiscal 2024.
- Jazz Pharmaceuticals plc operating lease, cost for fiscal 2024 was $22.21M, a 14.51% increase from fiscal 2023.
- Jazz Pharmaceuticals plc operating lease, cost for fiscal 2023 was $19.39M, a 1.40% decline from fiscal 2022.
- Jazz Pharmaceuticals plc operating lease, cost for fiscal 2022 was $19.67M, a 17.59% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $23.92M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $22.21M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $19.39M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $19.67M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $11.72M derived: sum of 2 quarters · filed 2024-02-28 | $18.32M derived: sum of 3 quarters · filed 2024-02-28 | $23.87M 10-K · filed 2024-02-28 |
| 2021-09-30 | $6.63M 10-Q · filed 2021-11-09 | $13.24M derived: sum of 2 quarters · filed 2021-11-09 | $18.78M 10-Q · filed 2021-11-09 | $24.34M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $6.60M 10-Q · filed 2021-08-03 | $12.15M 10-Q · filed 2021-08-03 | $17.70M derived: sum of 3 quarters · filed 2023-03-01 | $23.20M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $5.55M 10-Q · filed 2021-05-04 | $11.10M derived: sum of 2 quarters · filed 2023-03-01 | $16.60M derived: sum of 3 quarters · filed 2023-03-01 | $22.01M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $11.05M derived: sum of 2 quarters · filed 2023-03-01 | $16.46M derived: sum of 3 quarters · filed 2023-03-01 | $21.75M 10-K · filed 2023-03-01 |
| 2020-09-30 | $5.50M 10-Q · filed 2021-11-09 | $10.91M derived: sum of 2 quarters · filed 2021-11-09 | $16.20M 10-Q · filed 2021-11-09 | $21.62M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $5.41M 10-Q · filed 2021-08-03 | $10.70M 10-Q · filed 2021-08-03 | $16.11M derived: sum of 3 quarters · filed 2022-03-01 | $21.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $5.29M 10-Q · filed 2021-05-04 | $10.71M derived: sum of 2 quarters · filed 2022-03-01 | $16.45M derived: sum of 3 quarters · filed 2022-03-01 | $22.51M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $11.16M derived: sum of 2 quarters · filed 2022-03-01 | $17.22M derived: sum of 3 quarters · filed 2022-03-01 | $23.09M 10-K · filed 2022-03-01 |
| 2019-09-30 | $5.75M 10-Q · filed 2020-11-02 | $11.80M derived: sum of 2 quarters · filed 2020-11-02 | $17.67M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $6.06M 10-Q · filed 2020-08-04 | $11.93M 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $5.87M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |